

Major Article

In vitro and *in silico* assessment of new beta amino ketones with antiplasmodial activity

Gabriela Camila Krombauer^[1] , Karla de Sena Guedes^[1] , Felipe Fingir Banfi^[1] ,
Renata Rachide Nunes^[2] , Amanda Luisa da Fonseca^[2] , Ezequias Pessoa de Siqueira^[3] ,
Jéssica Côrrea Bezerra Bellei^[4] , Kézia Katiani Gorza Scopel^[4] , Fernando de Pilla Varotti^[2] 
and Bruno Antônio Marinho Sanchez^[1] 

[1]. Universidade Federal de Mato Grosso, Núcleo de Pesquisa e Apoio Didático em Saúde, Laboratório de Imunopatologia e Doenças Tropicais, Sinop, MT, Brasil.

[2]. Universidade Federal de São João Del Rei, Campus Centro Oeste, Núcleo de Pesquisa em Química Biológica (NQBio), Divinópolis, MG, Brasil.

[3]. Fundação Oswaldo Cruz, Instituto René Rachou, Laboratório de Química, Belo Horizonte, MG, Brasil.

[4]. Universidade Federal de Juiz de Fora, Centro de Pesquisas em Parasitologia, Departamento de Parasitologia, Microbiologia e Imunologia, Juiz de Fora, MG, Brasil.

ABSTRACT

Background: Based on the current need for new drugs against malaria, our study evaluated eight beta amino ketones *in silico* and *in vitro* for potential antimalarial activity.

Methods: Using the Brazilian Malaria Molecular Targets (BraMMT) and OCTOPUS® software programs, the pattern of interactions of beta-amino ketones was described against different proteins of *P. falciparum* and screened to evaluate their physicochemical properties. The *in vitro* antiplasmodial activities of the compounds were evaluated using a SYBR Green-based assay. In parallel, *in vitro* cytotoxic data were obtained using the MTT assay.

Results: Among the eight compounds, compound 1 was the most active and selective against *P. falciparum* ($IC_{50} = 0.98 \mu M$; $SI > 60$). Six targets were identified in BraMMT that interact with compounds exhibiting a stronger binding energy than the crystallographic ligand: *P. falciparum* triphosphate phosphoglycolate complex (1LYX), *P. falciparum* reductase (2OK8), PfPK7 (2PML), *P. falciparum* glutaredoxin (4NOZ), PfATP6, and PfHT.

Conclusions: The physicochemical properties of compound 1 were compatible with the set of criteria established by the Lipinski rule and demonstrated its potential as a drug prototype for antiplasmodial activity.

Keywords: Malaria. Chemotherapy. Antimalarial. Docking.

INTRODUCTION

Malaria continues to be one of the most important public health problems, with an estimated > 400,000 deaths each year^{1,2}. In humans, the disease is caused by the protozoan species of the *Plasmodium* genus³.

Although several substances are used in antimalarial chemotherapy, many of them are no longer used for treatment

because of their side effects or the development of parasitic resistance⁴⁻¹¹. Therefore, new strategies should be used, such as the addition of a third drug with independent antiparasitic activity¹⁰.

Computational tools have been employed to understand complex interactions in biological models¹².

The main objective of the computational model is to replicate the patterns of biological systems¹³ with a high accuracy. *In silico*

Corresponding author: Fernando de Pilla Varotti. e-mail: varotti@ufsj.edu.br

Authors' contribution: GCK, KdeSG, FFB, KKGS, CL and JCB: Performed the *in vitro* tests. EPS: Performed the synthesis of the compounds. CdeSB: Structural elucidation of the compounds. ALdaF and RRN: Performed *in silico* tests. BAMS and FdePV: Coordinated the study and project administration. All authors read and approved the manuscript.

Conflict of Interest: The authors declare that there is no conflict of interest.

Financial Support: This work was financially supported by the Fundação de Amparo à Pesquisa do Estado de Mato Grosso – FAPEMAT [042/2016], National Council for Scientific and Technological Development – CNPq, FAPEMIG, and Capes (Finance Code 001) for postdoctoral fellowship.

Received 7 December 2021 | **Accepted** 24 June 2022

models that achieve this goal are an important complement to experimental studies and can provide valuable insights into the mode of action of bioactive compounds¹⁴.

In this context, virtual screening (VS) is an important methodology in the discovery process of new antimalarial candidates¹⁵ and enables the identification of potential targets, contributing to the elucidation of its mechanism of action¹⁶.

Heterocyclic compounds are potential pharmacotherapeutic agents, which include antihypertensive effects and antimicrobials¹⁷⁻²⁰. Morpholine, piperidine, and their derivatives are examples of heterocyclic compounds that contain a nitrogen atom²¹⁻³¹. In the specific context of malaria, piperidine derivatives are low-cost synthesized compounds with efficient antimalarial activity³². In addition, morpholine scaffolds have already been proven to be good starting points for the development of new antimalarial candidates³³.

Thus, VS associated with biological assays is an increasingly useful approach for developing tools to identify potential antimalarial scaffolds³⁴. Therefore, the present study aimed to evaluate the antiplasmodial activities of eight compounds synthesized from beta-amine ketones *in silico* and *in vitro*.

METHODS

Synthesis, Purification and Structural elucidation

Eight molecules were obtained: morpholines (1, 3, 5, and 6) and piperidines (2, 4, 7, and 8) (**Figure 1**). A description is provided in the supplementary material.

Antiplasmodial activity

P. falciparum strain W2 (chloroquine-resistant) was cultured as previously described^{36,37}. The antiplasmodial activity of β -amino-ketones (compounds 1-8) against *P. falciparum* cultures was evaluated using SYBR³⁸. Ring-stage parasites were equally distributed in 96-well microculture plates. Serial dilutions of the compounds were performed ranging from 0.01 to 100 $\mu\text{g}/\text{mL}$. Chloroquine (CQ) was used as the antimalarial control. A fluorometer (Fluoroskan Ascent, Thermo Laboratories) with excitation at 485 nm and emission at 535 nm was used to determine the viability of the parasites. All experiments were performed in triplicates. Results are expressed as the mean of the IC_{50} (drug concentration that reduced parasite viability by 50%).


In vitro cytotoxicity

All compounds were assessed against WI-26VA4 (ATCC CCL-95.1, USA) human pulmonary fibroblast cells by MTT assay³⁹. Cells were cultured in RPMI-1640 medium (Sigma-Aldrich®, St. Louis, Missouri, USA) supplemented with 10% fetal bovine serum in 96-well plates⁴⁰. Compounds 1-8 were diluted to concentrations ranging from 0.2-200 $\mu\text{g}/\text{mL}$ and incubated for 48 h in a 5% CO_2 atmosphere at 37 °C.

Cellular viability was determined at 540 nm to measure the signal and background (Spectra Max340PC, Molecular Devices, Sunnyvale, California, USA). The minimum lethal dose for 50% of the cells (LD_{50}) was determined as previously described⁴¹.

Selectivity index (SI)

Selectivity index (SI) is the ratio between the values of LD_{50} and IC_{50} cytotoxicity of each compound tested. Values greater than 10 were considered low cytotoxic, whereas values below 10 were considered cytotoxic⁴².



Statistical analysis

IC_{50} and LD_{50} were determined using the equation of the curve obtained by plotting parasitemia reduction (%) or cellular death (%) vs. the concentration of the compound (log scale) using the GraphPad Prism software (version 5.0 for Windows, San Diego, California, USA). Due to the non-normality of the data distribution, the comparison of IC_{50} and LD_{50} between morpholine and piperidine was analyzed using the nonparametric Mann-Whitney U test. Statistical significance was defined at 5% ($p < 0.05$).

Evaluation of virtual screening and ADMET properties

Description is available in the supplementary material.

RESULTS

Antiplasmodial activity

The antiplasmodial activities of these eight compounds are listed in **Table 1**. IC_{50} values in the *in vitro* antimalarial tests (W2 strain) ranged from 0.98 μM to 47.95 μM . Compounds 1 and 4 had IC_{50} values close to those of chloroquine, a standard antimalarial drug. There was no statistically significant difference in IC_{50} or LD_{50} between parasites treated with morpholine and piperidine ($p = 0.225$ and $p = 0.593$, respectively).

Cytotoxic activity

The compounds did not show cytotoxic activity, since the LD_{50} values ranged from 33.97 μM to $> 100 \mu\text{M}$ compared to the control drug (chloroquine) (**Table 1**).

Compounds 2, 3, and 8 were not selective, with SI values below 10 (9.46, 3.07, and 0.81, respectively). Compounds 1, 4, 5, 6, and 7 showed the highest selectivity ($\text{SI} > 10$), with values ranging from 20.44 to 128.21 (**Table 1**).

TABLE 1: Morpholines and piperidines antiplasmodial activity.

Compounds	IC ₅₀ ± SD (µM)*	LD ₅₀ ^a ± SD (µM)*	SI
Morpholines			
1	0.98 ± 0.01	59.78 ± 6.83	61
3	32.53 ± 0.02	>100	3.07
5	3.93 ± 0.01	80.32 ± 9.03	20.44
6	3.93 ± 0.02	94.45 ± 18.90	24.03
Piperidines			
2	3.59 ± 0.08	33.97 ± 18.91	9.46
4	0.78 ± 0.09	>100	128.21
7	2.49 ± 0.03	>100	40.16
8	47.95 ± 18.51	38.82 ± 1.16	0.81
Chloroquine (CQ)	0.92 ± 0.01	>100	108.70

Drug concentration that reduced parasite viability in 50% (IC₅₀) and WI-26VA4 cells viability in 50% (LD₅₀), and selectivity index (SI) values of the compounds. *Mean and standard deviation (SD) of triplicate experiments. The test of the hypothesis of equality of IC₅₀ and LD₅₀ between the morpholine and piperidine groups was p=0.225 and 0.593, respectively (Mann-Whitney U test).

Compound 1 stood out for its IC₅₀ corresponding to 0.98, as well as for its SI of 61 and the values of binding energy it exhibited against the targets presented in BraMMT (Brazilian Malaria Molecular Targets), as described below.

Therefore, the docking assay and physicochemical properties of this compound were analyzed.

Virtual screening

Table 2 presents the molecular targets, locations, and enzymatic classes of the 35 proteins listed in the Brazilian Malaria Molecular Targets (BraMMT). Virtual screening of the compounds was performed against all 35 BraMMT.

As shown in Table 3, six of the 35 targets that make up BraMMT interacted with compounds 1-8, presenting binding energies superior to the crystallographic data. The six targets that were linked to the compounds were: *P. falciparum* triphosphate phosphoglycolate complex (1LYX), ferredoxin-NADP + *P. falciparum* reductase (2OK8), crystal structure of PfPK7 (2PML), oxireduction protein of *P. falciparum* glutaredoxin (4N0Z), *P. falciparum* ATPase orthologous calcium pump (PfATP6), and *P. falciparum* hexose transporter (PfHT). Compound 4 stood out on presenting the most satisfactory result, establishing a connection with the six targets, and presenting a higher binding value than the crystallographic data.

All tested compounds (1-8) interacted with the 2OK8 target, in which they obtained a stronger binding energy with the target than the crystallographic ligand. Compounds 1, 2, 3, 4, 6, and 8 interacted with the 4N0Z target. Compound 4 interacted with PfATP6, obtaining a similar value of binding energy (-7.3 kcal/mol) with the target compared to the crystallographic ligand (-7.2 kcal/mol).

Compounds 1 (-6.5 kcal/mol), 2 (-6.7 kcal/mol), 3 (-6.3 kcal/mol), 4 (-6.5 kcal/mol), 6 (-5.9 kcal/mol), and 8 (-6.1 kcal/mol) obtained stronger binding energy with the target than the crystallographic ligand (-5.7 kcal/mol), demonstrating interaction with PfHT.

Furthermore, compound 1 stood out in the antimalarial and cytotoxicity tests and was therefore chosen for intermolecular and physicochemical analyses.

Figure 2 shows a two-dimensional map of linker-receptor interactions with PfHT and the chemical bonds between compound 1 and the target. Pharmacophoric groups and possible structural improvements in permeability, absorption, and oral bioavailability have been indicated. By analyzing the molecular interactions of 1 with PfHT, it was possible to observe the interaction of 1 with GLN169 and THR145 residues (Figure 2). Molecular anchoring with D-glucose was performed to recognize the interactions at the PfHT binding site.

Tests of physicochemical properties

Supplementary Table 1 shows SwissADME profiles of compound 1 and chloroquine. Compound 1 had a CLogP <5 (1.67) and a molecular weight less than 500 g/mol (219.28 g/mol) (Supplementary Table 1). There were three hydrogen acceptor groups that performed the interactions and no hydrogen donor groups.

Compounds with CLogP values less than 3 present a low risk of side effects and toxicity, which indicates a low risk of retention and storage of the compound. Patterns of mutagenicity, tumorigenicity, and irritability were not associated with the molecular structure of compound 1, corroborating the literature, since this compound had CLogP <3 (Supplementary Table 1).

In addition, compound 1 had a superior synthetic facility compared to chloroquine, standing out for its solubility in water.

DISCUSSION


The committee coordinated by the Global Health Innovative Technology (GHIT) foundation, guided by the specific requirements for the disease and considering the target product and candidate profiles, defined a set of criteria in an attempt to validate new antimalarial candidates. These criteria were divided into validation

TABLE 2: Brazilian Malaria Molecular Targets (BraMMT).

PDB Code	Name	Enzymatic class	Location
1LF3	Plasmepsin II	Hydrolase	Digestive vacuole
1LYX	Triosephosphate Isomerase (PFTIM)-Phosphoglycolate	Isomerase	Cytoplasm
1NHW	Enoyl-acyl-carrier-protein reductase	Oxidoreductase	Apicoplast
1O5X	Triosephosphate Isomerase	Isomerase	Cytoplasm
1QNG	Peptidyl-prolyl cis-trans isomerase	Isomerase	Cytoplasm
1RL4	Formylmethionine deformylase	Hydrolase	Apicoplast
1TV5	Dihydroorotate dehydrogenase	Oxidoreductase	Cytoplasm e Nucleus
1U4O	L-lactate dehydrogenase	Oxidoreductase	Cytoplasm
1YWG	glyceraldehyde-3-phosphate dehydrogenase	Oxidoreductase	Cytoplasm
2AAW	Glutathione s-transferase	Transferase	Cytoplasm
2ANL	Plasmepsin IV	Hidrolase	Digestive vacuole
2OK8	Putative ferredoxin--NADP reductase	Oxidoreductase	Apicoplast
2PML	Ser/Thr protein kinase	Transferase	Cytoplasm
2Q8Z	Orotidine-monophosphate-decarboxylase	Liase	Nucleus
2VFA	Hypoxantine-guanine phosphoribosyltransferase	Transferase	Apicoplast
2VN1	70 KDA peptidylprolyl isomerase	Isomerase	Nucleus
2YOG	Thymidylate kinase	Transferase	Nucleus
3AZB	Beta-hydroxyacyl-ACP dehydratase	Lyase	Cytoplasm
3BPF	Falcipain II	Hydrolase	Digestive vacuole
3CLV	Rab5 Protein	Signaling protein	Cytoplasm
3FNU	HAP Protein	Hydrolase	Digestive vacuole
3K7Y	Aspartate aminotransferase	Transferase	Cytoplasm
3N3M	Orotidine 5'-phosphate decarboxylase	Lyase	Apicoplast
3PHC	Purine nucleoside phosphorylase	Transferase	Nucleus
3QS1	Plasmepsin I	Hydrolase	Digestive vacuole
3T64	Deoxyuridine 5'-triphosphate nucleotidohydrolase	Hydrolase	Nucleus
3TLX	Adenylate kinase 2	Transferase	Cytoplasm and mitochondria
4B1B	Thioredoxin reductase	Oxidoreductase	Cytoplasm
4C81	22-C-Methyl-D-Erythritol 2,4-Cyclodiphosphate synthase	Lyase	Apicoplast
4J56	Thioredoxin reductase 2	Oxidoreductase	Cytoplasm
4N0Z	Glutaredoxin	Oxidoreductase	Cytoplasm
4P7S	Macrophage migration inhibitory factor-like protein	Cytokine inhibitor	Cytoplasm
4QOX	Calcium-dependent protein kinase 4	Transferase	Cytoplasm
PfATP6	Calcium pump ortholog ATPase	Transporter	Membrane
PfHT (10.5452/ma-aej21)	Hexose carrier protein	Transporter	Membrane

TABLE 3: Binding energies of compounds against BRAMMT targets (kcal.mol⁻¹).

Compounds	Molecular targets						
	Binding energy (kcal.mol ⁻¹)						
	1LYX	2OK8	2PML	4NOZ	PfATP6	PfHT	
1	-5.9	-4.4	-6.6	-4.9	-6.3	-6.5	
3	-5.5	-4.5	-7.0	-4.9	-6.8	-6.3	
5	-5.9	-3.6	-5.9	-4.1	-5.5	-5.6	
6	-5.5	-3.7	-6.2	-4.3	-6.0	-5.9	
2	-5.8	-4.4	-7.1	-4.6	-6.8	-6.7	
4	-5.8	-4.6	-6.9	-4.7	-7.3	-6.5	
7	-5.8	-3.7	-5.8	-4.2	-6.1	-5.5	
8	-4.8	-3.7	-6.3	-4.3	-6.1	-6.1	
Crystallographic	-5.6	-2.0	-6.9	-4.3	-7.2	-5.7	



and activity/mechanism of action, LD₅₀ values for cell lines, IC₅₀ of the parasite, and selectivity index. The compounds must be tested according to the study of the life cycle of *Plasmodium* to evaluate their mechanism of action, correlating the manifestations of malaria. The main tests must be performed according to the target to ensure the characterization of the potential target candidate⁴⁹.

The *in vitro* cultivation of *P. falciparum* strains is the main test model for screening new compounds and monitoring resistance to antimalarial drugs, since it is possible to observe the activity, dosage, and resistance of natural and synthetic compounds through these tests⁵⁰.

IC₅₀ values must be <1 μM to validate compounds or effective compounds for *Plasmodium spp.* The selectivity index must be greater than 10 (LD₅₀ for the cell line relative to the IC₅₀ of the parasite) for *Plasmodium spp.*⁴⁹. Thus, compound 1 meets two parameters with IC₅₀ < 0.98 μM and IS=61. Compounds 4, 5, 6, and 7 presented selectivity indices of 128, 20.44, 24, and 40.16, respectively, which are satisfactory; however, the IC₅₀ was higher than 1 μM.

A study evaluating the antimalarial activity of alkaloids isolated from *Aspidosperma ulei* marker demonstrated IC₅₀ values close to 20 μM, indicating moderate activity against chloroquine-resistant *P. falciparum* strains⁵¹. According to these parameters, compounds

1 (0.98 μM), 2 (<3.59 μM), 5 (3.93 μM), and 6 (<3.93) were considered potentially active.

In a study by Ohashi⁵², it was demonstrated that the potential activity of a given compound varies between the protozoan species, obtaining different SI values according to the species analyzed. These results demonstrate that it is essential to understand the mechanisms of action of the compounds and cell lines used in the cell viability tests, in addition to the activity of the analyzed substances. Compound 1 stood out for its IC_{50} of 0.98, as well as an IS of 61. Thus, the physicochemical properties of this compound were analyzed.

Virtual screening of substances derived from the Mannich reaction was performed using 35 molecular targets obtained from BRAMMT. As shown in **Table 3**, 1LYX, 2OK8, 2PML, 4NOZ, PfATP6, and PfHT targets presented the best binding energy values for the compounds.

Using the BraMMT tool, the identification of a potential target is crucial in the discovery and rational development of new drugs to show their biological importance concurrently with the validation of the methodology to be used⁵³. Each *P. falciparum* target present in the bank was used to perform virtual screening and was identified according to its registration in the Protein Data Bank.

Ferredoxin-NADP + reductase from *P. falciparum* (PDB code: 2OK8) is associated with apicoplast metabolic pathways, a key organelle for parasite survival. Thus, *P. falciparum* exhibits a ferredoxin-NADP + reductase, giving rise to reduced ferredoxin for the essential biosynthetic pathways of the apicoplast⁵⁴. All tested substances (1-8) obtained binding energies stronger than the crystallographic ligand with the 2OK8 target.

P. falciparum glutaredoxin 1 (PDB 4NOZ) is an oxireduction protein present in the cytoplasm of the parasite that uses glutathione as a cofactor (glutaredoxin). This protein is exclusively found in *Plasmodium* species and plays a role in the central performance of maintaining parasite homeostasis⁵⁵. Compounds 1, 2, 3, 4, 6, and 8q exhibited stronger binding energies with the 4NOZ target than with the crystallographic ligand.

P. falciparum ATPase orthologous calcium pump (PDB PfATP6) is present in the sarcoplasmic reticulum of *P. falciparum*. The cytoplasmic calcium concentration increases with inhibition and therefore compromises the parasite's signaling pathways⁵⁶. Compound 4 obtained a higher binding energy value with the target than that of the crystallographic ligand, presenting a binding energy of $-73 \text{ kcal}\cdot\text{mol}^{-1}$ compared to the value of $-72 \text{ kcal}\cdot\text{mol}^{-1}$ of the crystallographic ligand, demonstrating an interaction with PfATP6.

The hexose transporter of *P. falciparum* (PDB PfHT) is a transmembrane protein responsible for glucose transport. Plasmodium requires glucose as its primary energy source during the erythrocytic cycle. Inhibition of glucose transport to infected cells impairs parasite viability. Therefore, substances that inhibit PfHT can be considered promising templates for developing new antimalarial compounds^{57,58,59}.

Compounds 1, 2, 3, 4, 6, and 8 exhibited stronger binding energies with PfHT than with the crystallographic ligand.

The *P. falciparum* Triosphosphate Isomerase Phosphoglycolate complex (PDB 1LYX) was also identified as a *P. falciparum* Triosephosphate isomerase (PFTIM). This consists of a catalytically

active enzyme, which is the subject of many studies because of its particularity at position 96. There is a serine residue in region 96 of triosphosphate isomerase in both humans and other organisms. However, the residue in PFTIM was replaced by a phenylalanine residue, with this enzyme being the only one to have serine in that position; however, so far, no specific role has been attributed to this particularity^{60,61}.

Differences were found when comparing the PFTIM structure with other TIM structures, especially that of humans, which can assist in modeling and developing therapeutic targets. One of these differences and particularities of PFTIM is in position 183, which has a completely exposed leucine, different from TIMs of other organisms, which have glutamate. It is believed that this exposed leucine residue, together with the positively charged surrounding adhesive, may be responsible for TIM binding to the erythrocyte membrane, which is important for the energy production of *Plasmodium*⁶².

The crystalline structure of PfPK7 in complex with an ATP analog (PDB 2PML) is a protein kinase that plays an important role in regulating the development of the parasite, by being involved in the signaling pathway of melatonin and modulating the life cycle of *P. falciparum*^{63,64}. PfPK7 is expressed in both the asexual and sexual stages of the parasite.

Dorin-Semblat et al.⁶⁵ demonstrated that interruption of the PfPK7 gene resulted in a reduction in the number of merozoites produced by each schizont, and the ability to produce oocysts in the mosquito was also impaired. These data reinforce the importance of PfPK7 in the parasite's life cycle⁶³. Several molecular targets, from subcellular organelles to metabolic pathways, have been described in the literature in an attempt to fight infection^{66,67}. Despite the numerous potential targets of pharmacological action, the most used compounds still date back many years: quinine, isolated from the *Cinchona sp.* in 1820 and artemisinin, purified from *Artemisia annua* in 1972, both extracted from natural sources⁶⁸.

P. falciparum hexose transporter (PfHT) has recently been characterized as promising for the development of new drugs^{59,60,69}. The reason for this is that the parasite is found inside erythrocytes surrounded by the parasitophorous vacuole, and glucose molecules must pass through its membrane before being transported to the parasite^{70,71}. Therefore, PfHT was characterized among BraMMT with similar or superior binding energy to the crystallographic ligand as a carrier target, which can contribute to the performance of the prototype compounds.

Compound 1 was chosen for the analysis of its physicochemical properties and intermolecular interactions according to its performance in antimalarial and toxicity tests. Compound 1 interacts with GLN169 and THR145 residues at the same D-glucose binding site in PfHT⁵⁹.

Figure 2 shows the electrostatic bonds and Van der Waals interactions with the PfHT receptor by the GLY41, SER45, ASN48, THR49, ASN52, ARG104, ILE141, VAL144, THR145, VAL148, PRO149, HIS168, GLN169, and ILE172 groups and the SER45, ASN48, ASN52, THR49, VAL144, THR145, VAL148, HIS168, GLN169, and ILE172 nuclei with D-glucose, indicating that the antimalarial activity is associated with the presence of these structures.

The hexose transporter for *P. falciparum* (PfHT) was recently described by molecular anchoring, QM/MM, and simulations of

molecular dynamics by our research group^{59,60}. **Figure 2** shows a two-dimensional map of ligand-receptor interactions with PfHT. The chemical bonds between the compound and the target are indicated. The two-dimensional structure of these compounds is also shown. Molecular anchoring with D-Glucose was performed to recognize the interactions at the PfHT binding site.

Identifying and characterizing pharmacologically active molecules is a necessity that has led to efforts in diverse areas of scientific research worldwide. The applicability of such molecules can be quite variable; however, the main objective of the drug development process is to obtain molecules with efficiency and specificity in relation to the therapeutic target, low cost, and absence or reduction of risks to potential users⁷².

The increase in resistance to current antimalarial drugs drives research that aims to understand the mechanism of action of compounds for parasitic diseases with social and economic impacts. This knowledge will assist in screening bioactive compounds with determined pharmacodynamic and/or pharmacokinetic characteristics⁷³. The methodologies used in this study have the main objective of characterizing potential targets, and these data and discussions allow us to infer the importance of the present study.

PfHT has characteristics similar to those of the human glucose transporter (GLUT1). However, there are some differences in their interactions with the substrates. PfHT can carry both D-glucose and D-fructose, whereas GLUT1 is selective for D-glucose and GLUT5 for D-fructose. Thus, PfHT can function as a pharmacological target in the development of antimalarials because of its selective affinity for different substrates^{74,75}.

In addition, fructose can be used as an energy source in *in vitro* cultures of *P. falciparum*. Concentrations at this stage are lower than those of glucose⁷⁶.

The blood phases of the parasite depend on glycolysis for energy production^{77,78}. Therefore, PfHT is a potential therapeutic target in the exoerythrocytic phase⁶⁹.

The Lipinski rule is one of the main descriptors used to analyze new prototype compounds for drugs. Thus, the physicochemical profiles of orally administered drugs are mainly based on the Lipinski rule, and it is possible to evaluate the absorption, distribution, metabolism, excretion, and toxicity of the compound, also known as the ADMET property^{79,80}. The physicochemical characteristics of a compound can be decisive in the success or failure of its biological activity⁸¹. New antimalarial candidates should exhibit good oral bioavailability and membrane permeability⁸². The SwissADME tool allows determination of the main physicochemical and pharmacokinetic *in silico* properties of compounds⁴⁷. **Supplementary Table 1** shows SwissADME profiles of compound 1 and chloroquine.

The partition coefficient (CLogP) is recommended for estimating the toxicological factors⁸³. It is known that compounds with high molecular weights and an excessive number of hydrogen acceptors and donor groups have higher difficulty crossing the lipid bilayer of cell membranes⁸⁴.

According to Lipinski's rule, compound 1 had a CLogP < 5 (1.67) and a molecular weight less than 500 g/mol (219.28 g/mol) (**Supplementary Table 1**). There were three hydrogen acceptor groups that interacted, and no hydrogen donor groups. These

data demonstrated that the ADMET properties of compound 1 were acceptable under Lipinski's rule.

A study by Gleeson⁸³ demonstrated that compounds with LogP less than 4 and molecular weight less than 400 g/mol had a promising ADMET profile. Thus, compound 1 also fits the presented criteria and therefore presents the appropriate ADMET properties according to Lipinski and Gleeson^{80,84}. Compounds with CLogP values less than 3 present a low risk of side effects and toxicity, indicating a low risk of the substance being trapped and stored. When analyzing the toxicological characteristics of compound 1, factors such as mutagenicity, tumorigenicity, or irritability were not detected (**Supplementary Table 1**). In addition, compound 1 has a superior synthetic facility compared to chloroquine, standing out for its solubility in water.

In conclusion, compound 1 has potential as a drug prototype owing to the presentation of appropriate characteristics such as absorption, toxicity, good solubility, low molecular weight, and permeability. These data corroborate the growing interest in synthetic morpholines, as well as the usage diversity of these compounds, as described by Kourounakis²⁰, since compound 1 stands out for its antiplasmodial and cytotoxic activity.

ACKNOWLEDGMENTS

We thank Brazilian National Council for Scientific and Technological Development (CNPq) process 303680/2021-0, Fundação de Amparo à Pesquisa do Estado de Minas Gerais - Brasil (FAPEMIG) and Fundação de Amparo à Pesquisa do Estado de Mato Grosso - Brasil (FAPEMAT) for financial support.

REFERENCES

- World Health Organization (WHO). World malaria report 2018. Geneva: WHO; 2018. 210 p.
- Organização Panamericana da Saúde (OPAS) [Internet]. Organização Mundial da Saúde (OMS). Malária. Brasília, 2016. [updated 2021 September 15; cited 2021 Sep 15]. Available from: <https://www.paho.org/pt/topicos/malaria>
- World Health Organization (WHO). World malaria report 2019. Geneva: WHO; 2019. 232 p.
- Brasil. Ministério da Saúde [Internet]. Situação epidemiológica da malária no Brasil. Secretaria de Vigilância em Saúde. Diretoria Técnica de Gestão. Brasília: Ministério da Saúde, 2018. [updated 2021 September 15; cited 2021 Sep 15]. Available from: <https://www.saude.gov.br/svs>
- França TCC, Santos MG, Figueroa-Villar JD. Malária: aspectos históricos e quimioterapia. Química Nova. 2008;31(5):1271-1278. Available from: <http://dx.doi.org/10.21577/0100-4042.20170710>.
- Menard D, Dondorp A. Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harb Perspect Med. 2017;7(7):a025619. Available from: <https://doi.org/10.1101/cshperspect.a025619>
- Nosten F, White NJ. Artemisinin-Based Combination Treatment of Falciparum Malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):181-92.
- Ocan M, Akena D, Nsoby S, Kanya MR, Senono R, Kinengyere AA, Obuku EA. Persistence of chloroquine resistance alleles in malaria endemic countries: a systematic review of burden and risk factors. Malar J. 2019;18(1):76. Available from: <https://doi.org/10.1186/s12936-019-2716-z>.
- White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999;354(1384):739-49. Available from: <https://doi.org/10.1098/rstb.1999.0426>.

10. White NJ. Antimalarial drug resistance. *J Clin Invest* 2004;113(8):1084-92. Available from: <https://doi.org/10.1172/JCI21682>.
11. Bakhiet AMA, Abdelraheem MH, Kheir A, Omer S, Gismelseed L, Abdel-Muhsin AA, et al. Evolution of *Plasmodium falciparum* drug resistance genes following artemisinin combination therapy in Sudan. *Trans R Soc Trop Med Hyg* 2019;113(11):693-700. Available from: <https://doi.org/10.1093/trstmh/trz059>.
12. Singh R, Bhardwaj VK, Sharma J, Das P, Purohit R. Identification of selective cyclin-dependent kinase 2 inhibitor from the library of pyrrolone-fused benzosuberene compounds: an *in silico* exploration. *J Biomol Struct Dyn*. 2021 Mar 22:1-9. doi: 10.1080/07391102.2021.1900918. Epub ahead of print. PMID: 33749525.
13. Brodland, GW. How computational models can help unlock biological systems, *Seminars in Cell & Developmental Biology*, Volumes 47-48, 2015, Pages 62-73, ISSN 1084-9521, <https://doi.org/10.1016/j.semdb.2015.07.001>.
14. Bhardwaj VK, Purohit R. Targeting the protein-protein interface pocket of Aurora-A-TPX2 complex: rational drug design and validation. *J Biomol Struct Dyn*. 2021 Jul;39(11):3882-3891. doi: 10.1080/07391102.2020.1772109. Epub 2020 Jun 8. PMID: 32448055.
15. Shibi IG, Aswathy L, Jisha RS, Masand VH, Gajbhiye JM. Virtual Screening Techniques to Probe the Antimalarial Activity of some Traditionally Used Phytochemicals. *Comb Chem High Throughput Screen*. 2016;19(7):572-91. doi: 10.2174/1386207319666160420141200. PMID: 27095535.
16. Banfi FF, Krombauer GC, da Fonseca AL, Nunes RR, Andrade SN, de Rezende MA, et al. Dehydrobufotenin extracted from the Amazonian toad *Rhinella marina* (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs. *J Venom Anim Toxins*, v. 27, p. 1-16, 2021.
17. Ghuge RB, Khadse AN. Vicinal Diaryl Pyrroles: Synthesis and Biological Aspects. *Vicinal Diaryl Substituted Heterocycles*. 2018;47-82. Available from: <https://doi.org/10.1016/B978-0-08-102237-5.00003-1>
18. Roth HJ, Kleemann A, Beissweger T. *Pharmaceutical chemistry: drug synthesis*. Books in Biological Sciences, Series in Pharmaceutical Technology. Hardcover – January 1, 1991.
19. Balaban AT, Oniciu DC, Katritzky AR. Aromaticity as a cornerstone of heterocyclic chemistry. *Chem Rev*. 2004;104(5):2777-2812. Available from: <https://doi.org/10.1021/cr0306790>
20. Kourouakis AP, Xanthopoulos D, Tzara A. Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological. *Med Res Rev*. 2020;40(2):709-752. Available from: <https://doi.org/10.1002/med.21634>
21. Ghorbani M, Bushra B, Zabiulla S, Mamatha SV. Piperazine and morpholine: Synthetic preview and pharmaceutical applications. *J Chem Pharm Res*. 2015;7(5):281-301. Available from: <https://doi.org/10.5958/0974-360X.2015.00100.6>
22. Pulch M. Preludin in therapy of obesity. *Deut Med J*. 1955;6(15-16):545-6.
23. Chrystelis MC, Reka EA, Kourounakis PN. Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. *J Med Chem*. 2000;43(4):609-612. Available from: <https://doi.org/10.1021/jm991039i>
24. Kaur H, Sapna DD, Jasbir S, Balasubramanian N. Morpholine based diazenyl chalcones: synthesis, antimicrobial screening and cytotoxicity study. *Anticancer Agents Med Chem*. 2018;18(15):2193-2205. Available from: <https://doi.org/10.2174/1871520618666180830152701>
25. Ahmadi A, Khalili M, Ramin H, Moslem N. New morpholine analogues of phencyclidine: Chemical synthesis and pain perception in rats. *Pharmacol Biochem Behav*. 2011;98(2):227-233. Available from: <https://doi.org/10.1016/j.pbb.2010.12.019>.
26. Arshad F, Khan MF, Akhtar W, Alam MM, Nainwal LM, Kaushik SK, Akhter M, Parvez S, Hasan SM, Shaquiquzzaman M. Revealing quinquennial anticancer journey of morpholine: A SAR based review. *Eur J Med Chem*. 2019;167:324-356. Available from: <https://doi.org/10.1016/j.ejmech.2019.02.015>
27. Leathen ML, Brandon RR, Wolfe JP. A new strategy for the synthesis of substituted morpholines. *J Org Chem*. 2009;74(14):5017-5110. Available from: <https://doi.org/10.1021/jo9007223>
28. Ford CW, Zurenko GE, Barbachy MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. *Curr Drug Targets Infect Disord*. 2001;1(2):181-199. Available from: <https://doi.org/10.2174/1568005014606099>
29. Abramova TV, Bakharev PA, Vasilyeva SV. Synthesis of morpholine nucleoside triphosphates. *Tetrahedron Lett*. 2004;45:4361-4364. Available from: <https://doi.org/10.1016/j.tetlet.2004.03.193>.
30. Pati B, Banerjee S. Importance of piperidine moiety in medicinal chemistry research: a review. *J Pharm Res*. 2012;5(12):5493-509.
31. Vardanyan R. Piperidine-based drug discovery. University of Arizona Tucson, AZ, United States. 1-347. 2017.
32. Seck R, Gassama A, Cojean S, Cavé C. Synthesis and Antimalarial Activity of 1,4-Disubstituted Piperidine Derivatives. *Molecules*. 2020;25(2):299. Published 2020 Jan 11. doi:10.3390/molecules25020299.
33. Upadhyay C, Sharma N, Kumar S, Sharma PP, Fontinha D, Chhikara BS, et al. 2022. Synthesis of the new analogs of morpholine and their antiplasmodial evaluation against the human malaria parasite *Plasmodium falciparum*. *New J. Chem.*, 2022, 46, 250-262. Doi: 10.1039/D1NJ04198C.
34. Fontinha D, Moulesm I, Prudêncio M. Repurposing Drugs to Fight Hepatic Malaria Parasites. *Molecules*. 2020;25(15):3409. Available from: <https://doi.org/10.3390/molecules25153409>
35. Mannich C, Krösche W. Ueber ein Kondensationsprodukt aus Formaldehyd, Ammoniak und Antipyrin. *Arch Pharm*. 1912;647-667.
36. Trager W, Jensen JB. Human malaria parasites in continuous culture. *Science*. 1976;193(4254):673-5.
37. Lambros C, Vanderberg JP. Synchronization of *Plasmodium falciparum* erythrocytic stages in culture. *J Parasitol*. 1979;65(3):418-20.
38. Vossen MG, Pferschys P, Chiba H, Noedl AM. The SYBR Green I malaria drug sensitivity assay: performance in low parasitemia samples. *Am J Trop Med Hyg*. 2010;82(3):398-401. Available from: <https://doi.org/10.4269/ajtmh.2010.09-0417>
39. Costa Junior DB, Araújo JSCA, Oliveira LM, Neri FSM, Moreira POL, Taranto AG, Fonseca AL da, Varotti FP, Leite FHA. Identification of novel antiplasmodial compound by hierarchical virtual screening and assays. *J Biomol Struct Dyn*. 2021;13:1-9. Available from: <https://doi.org/10.1080/07391102.2020.1763837>
40. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. *J Immunol Methods*. 1986;89(2):271-7. Available from: [https://doi.org/10.1016/0022-1759\(86\)90368-6](https://doi.org/10.1016/0022-1759(86)90368-6)
41. Valsalam S, Agastian P, Esmail GA, Ghilan AM, Al-Dhabi NA, Arasu MV. Biosynthesis of silver and gold nanoparticles using *Musa acuminata* colla flower and its pharmaceutical activity against bacteria and anticancer efficacy. *J Photochem Photobiol B*. 2019;201:111670. Available from: <https://doi.org/10.1016/j.jphotobiol.2019.111670>.

42. Bell CA, Hall JE, Kyle DE, Grogl M, Ohemeng KA, Allen MA, Tidwell RR. Structure-activity relationships of analogs of pentamidine against *Plasmodium falciparum* and *Leishmania mexicana amazonensis*. *Antimicrob Agents Chemother*. 1990;34(7):1381-6.
43. Jaghoori MM, Bleijlevens B, Olabbariaga SD. 1001 ways to run AutoDock Vina for virtual screening. *J Comput Aided Mol. Des*. 2016;30(3):237-249. Available from: <https://doi.org/10.1007/s10822-016-9900-9>.
44. Nunes R R, Fonseca AL, Pinto ACS, Maia EHB, Silva AM, Varotti FP, Taranto AG. Brazilian malaria molecular targets (BraMMT): selected receptors for virtual high-throughput screening experiments. *Mem Inst Oswaldo Cruz*. 2019;114:1-10. Available from: <https://doi.org/10.1590/0074-02760180465>
45. Maia EH, Campos VA, Dos Reis Santos B, Costa MS, Lima IG, Greco SJ, Ribeiro RIMA, Munayer FM, Silva AM da, Taranto AG. Octopus: a platform for the virtual high-throughput screening of a pool of compounds against a set of molecular targets. *J Mol Model*. 2017;23(1):26. Available from: <https://doi.org/10.1007/s00894-016-3184-9>
46. Maia EHB, Medaglia LR, Silva AM, Taranto AG. Molecular architect: A user-friendly workflow for virtual screening. *ACS Omega*. 2020;5:6628-6640. Available from: <https://doi.org/10.1021/acsomega.9b04403>
47. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep*. 2017;7:42717. Available from: <https://doi.org/10.1038/srep42717>
48. Sander T, Freyss J, Von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. *J Chem Inf Model*. 2015;55(2):460-473. Available from: <https://doi.org/10.1021/ci500588j>
49. Katsuno K, Burrows JN, Duncanm K, Huijsduijnenm RHV, Kaneko T, Kita K, Mowbray CE, Schmatz D, Warner P, Slingsby BT. Hit and lead criteria in drug discovery for infectious diseases of the developing world. *Nat Rev Drug Discov*. 2015;14(11):751-758. Available from: <https://doi.org/10.1038/nrd4683>
50. Wong RPM, Lautu D, Tayul SLH, Siba P, Karunajeewa HA, Ilett KF, Mueller I, Davis TME. In vitro sensitivity of *Plasmodium falciparum* to conventional and novel antimalarial drugs in Papua New Guinea. *Trop Med Int Health*. 2010;15(3):342-9. Available from: <https://doi.org/10.1111/j.1365-3156.2009.02463.x>
51. Torres ZES, Silveira ER, Silva LFR, Lima ES, Vasconcellos MC, Uchoa DEA, Bra R, Pohlit AM. Chemical composition of *Aspidosperma ulei* Markgr. and antiplasmodial activity of selected indole alkaloids. *Molecules*. 2013;18(6):6281-97. Available from: <https://doi.org/10.3390/molecules18066281>
52. Ohashi M, Amoa-Bosompem M, Kwofie KD, Agyapong J, Adegle R, Sakyiamah MM, et al. In vitro antiprotozoan activity and mechanisms of action of selected Ghanaian medicinal plants against *Trypanosoma*, *Leishmania*, and *Plasmodium* parasites. *Phytother Res*. 2018;32(8):1617-1630. Available from: <https://doi.org/10.1002/ptr.6093>
53. Sousa SF, Cerqueira NMFS, Fernandes PA, Ramos MJ. Virtual screening in drug design and development. *Comb Chem High Throughput Screen*. 2010;13(5):442-53. Available from: <https://doi.org/10.2174/138620710791293001>
54. Suwito H, Jumina M, Pudjiastuti P, Fanani MZ, Kimata-Arigo Y, Katahira R, Kawakami T, Fujiwara T, Hase T, Sirat HM, Puspaningsih NNT. Design and Synthesis of Chalcone Derivatives as Inhibitors of the ferredoxin - ferredoxin-NADP+ Reductase Interaction of *Plasmodium falciparum*: Pursuing new antimalarial agents. *Molecules*. 2014;19(12):21473-88. Available from: <https://doi.org/10.3390/molecules191221473>
55. Yogavel M, Tripathi T, Gupta A, Banday MM, Rahlfs S, Becker K, Belrhali H, Sharma A. Atomic resolution crystal structure of glutaredoxin 1 from *Plasmodium falciparum* and comparison with other glutaredoxins. *Acta Crystallogr. D Biol Crystallogr*. 2014;70(1):91-100. Available from: <https://doi.org/10.1107/S1399004713025285>.
56. Hotta CT, Gazarini ML, Beraldo FH, Varotti FP, Lopes C, Markus RP, Pozzan T, Garcia CR. Calcium-dependent modulation by melatonin of the circadian rhythm in malarial parasites. *Nat Cell Biol*. 2000;2(7):466-468. Available from: <https://doi.org/10.1038/35017112>
57. Leite FH, Fonseca AL da., Nunes RR, Comar Júnior M, Varotti FP, Taranto AG. Malaria: From old drugs to new molecular targets. *Biotechnol Rep*. 2013;2(4):59-76.
58. Fonseca AL, Nunes RR, Braga VLM, Comar Júnior M, Alves RJ, Varotti FP, Taranto, AG. Docking, QM/MM, and molecular dynamics simulations of the hexose transporter from *Plasmodium falciparum* (PfHT). *J Mol Graph Model*. 2016;66:174-186. Available from: <https://doi.org/10.1016/j.jmgm.2016.03.015>
59. Fonseca A L da, Nunes RR, Comar Júnior M, Alves RJ, Varotti FP, Taranto AG. Structural determination of hexose transporter *Plasmodium falciparum* (PfHT) by homology modeling. *Model Archive*. 2017. Available from: <https://doi.org/10.5452/ma-aej21>
60. Parthasarathy S, Eaazisai K, Balaran H, Balaran P, Murthy MRN. Structure of *Plasmodium falciparum* Triose-phosphate Isomerase-2-Phosphoglycerate Complex at 1.1-Å Resolution *J Biol Chem*. 2003;278(52):52461-70. Available from: <https://doi.org/10.1074/jbc.M308525200>
61. Ravindra G, Balaran P. *Plasmodium falciparum* triosephosphate isomerase: New insights into an old enzyme. *Pure Appl Chem*. 2005;77(1): 281-289. Available from: <https://doi.org/10.1351/pac200577010281>
62. Velanker SS, Ray SS, Gokhale RS, Suma S, Balaran P, Murthy MR. Triosephosphate isomerase from *Plasmodium falciparum*: the crystal structure provides insights into antimalarial drug design. *Structure*. 1997;5(6):751-61. Available from: [https://doi.org/10.1016/s0969-2126\(97\)00230-x](https://doi.org/10.1016/s0969-2126(97)00230-x)
63. Pease BN. Characterization of *Plasmodium falciparum* Atypical Kinase Pfpk7-Dependent Phosphoproteome. *J Proteome Res*. 2018;17(6):2112-2123. Available from: <https://doi.org/10.1021/acs.jpoteome.8b00062>
64. Koyama FC, Ribeiro RY, Garcia JL, Azevedo MF, Chakrabarti D, Garcia CRS. Ubiquitin proteasome system and the atypical kinase Pfpk7 are involved in melatonin signaling in *Plasmodium falciparum*. *J Pineal Res*. 2021;53(2):147-153. Available from: <https://doi.org/10.1111/j.1600-079X.2012.00981.x>
65. Dorin-Semlat D, Sicard A, Doerig C, Ranford-Carwright L, Doerig C. Disruption of the Pfpk7 gene impairs schizogony and sporogony in the human malaria parasite *Plasmodium falciparum*. *Eukaryot Cell*. 2008;7(2):279-285. Available from: <https://doi.org/10.1128/EC.00245-07>
66. Greenwood BM, Fidock DA, Kyle DE, Kappe SHI, Alonso PL, Collins FH, Duffy PE. Malaria: progress, perils, and prospects for eradication. *J Clin Invest*. 2008;118(4):1266-1276. Available from: <https://doi.org/10.1172/JCI33996>
67. Martin RF, Ginsburg H, Kirk K. Membrane transport proteins of the malaria parasite. *Mol Microbiol*. 2009;74(3):519-528. Available from: <https://doi.org/10.1111/j.1365-2958.2009.06863.x>
68. Croft TSL. Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery. *Drug Discov Today*. 2001;6(21):1151. Available from: [https://doi.org/10.1016/s1359-6446\(01\)02035-9](https://doi.org/10.1016/s1359-6446(01)02035-9)

69. Joët T, Eckstein-Ludwig U, Morin C, Krishna S. Validation of the hexose transporter of *Plasmodium falciparum* as a novel drug target. *Proc Natl Acad Sci USA*. 2003;100(13):7476-7479. Available from: <https://doi.org/10.1073/pnas.1330865100>
70. Desai SA, Krogstad DJ, McCleskey EW. A nutrient-permeable channel on the intraerythrocytic malaria parasite. *Nature*. 1993;362(6421):643-646. Available from: <https://doi.org/10.1038/362643a0>
71. Desai SA, Rosenberg RL. Pore size of the malaria parasite's nutrient channel. *Proc Natl Acad Sci USA*. 1997;94(5):2045-2049. Available from: <https://doi.org/10.1073/pnas.94.5.2045>.
72. Bhatnagar ISK. Marine Antitumor Drugs: Status, Shortfalls and Strategies. *Mar Drugs*. 2010;8(10):2702-2720. Available from: <https://doi.org/10.3390/md8102702>
73. Skinner-Adams T, Sumanadasa SDM, Fisher GM, Davis RA, Doolan DL, Andrews KT. Defining the targets of antiparasitic compounds. *Drug Discov Today*. 2016;(5):725-39. Available from: <https://doi.org/10.1016/j.drudis.2016.01.002>
74. Ionita M, Krishna S, Léo PM, Morin C, Patel AP. Interaction of o-(undec-10-en)-yl-d-glucose derivatives with the *Plasmodium falciparum* hexose transporter (pfht). *Bioorganic Med Chem Lett*. 2007;17(17):4934-4937. Available from: <https://doi.org/10.1016/j.bmcl.2007.06.021>
75. Slavic K, Krishna S, Derbyshire T, Staines H. Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa. *Malar J*. 2011;10:165. Available from: <https://doi.org/10.1186/1475-2875-10-165>
76. Woodrow CJ, Burchmore A. Hexose permeation pathways in *Plasmodium falciparum*-infected erythrocytes. *Proc Natl Acad Sci USA*. 2000;97(18):9931-6. Available from: <https://doi.org/10.1073/pnas.170153097>
77. Krishna S, Eckstein-Ludwig U, Uhlemann AC, Morin C, Webb R, Woodrow C, Kun JFJ, Kreamsner PG. Transport processes in *Plasmodium falciparum*-infected erythrocytes: potential as new drug targets. *Int J Parasitol*. 2002;32(13):1567-1573. Available from: [https://doi.org/10.1016/s0020-7519\(02\)00185-6](https://doi.org/10.1016/s0020-7519(02)00185-6)
78. Chen X, Chong CR, Shi L, Yoshimoto T, Sulivann Jr D, Liu JO. Inhibitors of *Plasmodium falciparum* methionineaminopeptidase 1b possess antimalarial activity. *Proc Natl Acad Sci USA*. 2006;103(39):14548-14553. Available from: <https://doi.org/10.1073/pnas.0604101103>
79. Lipinski CA, Lombardo F, Dominy BW, Freeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev*. 1997;23(1):3-25. Available from: [https://doi.org/10.1016/s0169-409x\(00\)00129-0](https://doi.org/10.1016/s0169-409x(00)00129-0)
80. Lipinski CA. Lead- and drug-like compounds: The rule-of-five revolution. *Drug Discov. Today Technol*. 2004;1(4):337-41. Available from: <https://doi.org/10.1016/j.ddtec.2004.11.007>
81. Doogue MP, Polasek TM. The ABCD of clinical pharmacokinetics. *Ther Adv Drug Saf*. 2013;4(1):5-7. Available from: <https://doi.org/10.1177/2042098612469335>
82. Guimarães DSM, Luz LSS, Nascimento SB do, Silva LR, Martins NRM, Almeida HG de, et al. Improvement of antimalarial activity of a 3-alkylpyridine alkaloid analog by replacing the pyridine ring to a thiazole-containing heterocycle: Mode of action, mutagenicity profile, and Caco-2 cell-based permeability. *Eur J Pharm Sci*. 2019;138:105015. Available from: <https://doi.org/10.1016/j.ejps.2019.105015>
83. Silva RL, Ferreira M. Estudo do coeficiente de partição octanol-água de bifenilas policloradas (PCBs) utilizando parâmetros topológicos. *Quím Nova*. 2003;26(3):312-318.
84. Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. *J Med Chem*. 2008;51(4):817-834. Available from: <https://doi.org/10.1021/jm701122q>

SUPPLEMENTARY TABLE 1: Physicochemical properties of compound 1 and chloroquine by SwissADME.

PHYSICOCHEMICAL PROPERTIES	1	CLOROQUINE
Formula	C ₁₃ H ₁₇ NO ₂	C ₁₈ H ₂₆ ClN ₃
Molecular weight	219.28 g/mol	319.87 g/mol
Nº, heavy atoms	16	22
Num. heavy atoms	6	10
Fractions Csp3	0.46	0.50
Num. rotate bonds	4	8
Num. H-bond Acceptor	3	2
Num. H-bond Donator	0	1
Molar Refractivity	66,45	97,41
TPSA	36.02 Å ²	28.16 Å ²
LIPOPHILICITY		
Log P _{ow} (ILOGP)	-2.4	3.95
Log P _{ow} (XLOGP3)	1.20	4.63
Log P _{ow} (WLOGP)	1.21	4.62
Log P _{ow} (MLOGP)	-1.05	3.20
Log P _{ow} (SILICOS-IT)	2.5	4.32
Consensus Log P _{ow}	1.67	4.15
WATER SOLUBILITY		
Log S (ESOL)	-1.97	-4.55
Solubility	2.35e+ mg/ml; 1.07e-02 mol/l	9.05e-03 mg/ml; 2.83e-05 mol/l
Class	Soluble	Moderately soluble
Log S (Ali)	-1.42	-4.95
Solubility	8.40e+00 mg/ml; 3.83e-02 mol/l	3.61e-03 mg/ml; 1.13e-05 mol/l
Class	Soluble	Moderately soluble
Log S (SILICOS-IT)	-3.35	-6.92
Solubility	9.82e-02 mg/ml; 4.48e-04 mol/l	3.86e-05 mg/ml; 1.21e-07 mol/l
Class	Soluble	Poorly soluble
PHARMACOKINETICS		
GI absorption	High	High
BBB permeant	Yes	Yes
P-gp substrate	No	No
CYP1A2 inhibitor	No	Yes
CYP2C19 inhibitor	No	No
CYP2C9 inhibitor	No	No
CYP2D6 inhibitor	No	Yes
CYP3A4 inhibitor	Yes	Yes
Log Kp (skin permeation)	-6.79 cm/s	-4.96 cm/s
DRUGLIKENESS		
Lipinski	Yes; 0 violation	Yes; 0 violation
Ghose	Yes	Yes
Veber	Yes	Yes
Egan	Yes	Yes
Muegge	Yes	Yes
Bioavailability Score	0.55	0.55
MEDICINAL CHEMISTRY		
PAINS	0 alert	0 alert
Brenk	0 alert	0 alert
Leandlikeness	No; 1 violation: MW<250	No; 2 violations: Rotors>7, XLOGP3>3.5
Synthetic accessibility	1.54	2.76

SYNTHESIS, PURIFICATION, AND STRUCTURAL ELUCIDATION

The compounds were synthesized according to the classical Mannich reaction using anhydrous ethanol as the solvent and morpholine and piperidine as secondary bases and respective ketones³⁵.

COMPOUNDS

Compound 1

3-(morpholin-4-yl)-1-phenylpropan-1-one:

First, 100 mL of anhydrous ethanol, 1.69 g of morpholine hydrochloride (13.66 mmol), 0.41 g paraformaldehyde (13.7 mmol), and 1.64 g acetophenone (13.66 mmol) were stirred under reflux in a sealed vial. The system was turned off after four hours and partitioned three times with water/ethyl acetate. The aqueous phase was collected and dried under vacuum. A small amount of solid residue was crystallized on acetone/ethanol to produce 2.1 g of compound 1 (9.6 mmol of hydrochloride salt) with a yield of 70%.

Compound 2

1-phenyl-3-(piperidin-1-yl)propan-1-one:

Second, 100 mL of anhydrous ethanol, 1.68 g of piperidine hydrochloride (13.82 mmol), 0.414 g paraformaldehyde (13.8 mmol), and 5.0 g of acetophenone (41.7 mmol) were stirred under reflux in a sealed vial. The system was turned off after three hours and partitioned three times with water/ethyl acetate. The aqueous phase was collected and dried under vacuum. The small solid residue was solubilized in acetone and crystallized overnight at a low temperature (-4 °C). The crystals were filtered and recrystallized to obtain 3.0 g of compound 2 (11.8 mmol, hydrochloride salt) with a yield of 86%.

Compound 3

2-methyl-3-(morpholin-4-yl)-1-phenylpropan-1-one:

Third, 100 mL of anhydrous ethanol, 5.5 g of morpholine hydrochloride (44.5 mmol), 1.35 g paraformaldehyde (45 mmol), and 1.5 g propylphenone (11.2 mmol) were stirred under reflux in a sealed vial. The system was turned off after four hours and partitioned three times with water/ethyl acetate. The aqueous phase was collected and dried under vacuum. The small amount of solid residue was crystallized in ethanol at 0 °C to produce 2.0 g of compound 3 (8.6 mmol of hydrochloride salt) with a yield of 76%.

Compound 4

2-methyl-1-phenyl-3-(piperidine-1-yl)propan-1-one:

Fourth, 100 mL of anhydrous ethanol, 1.37 g of piperidine hydrochloride (11.3 mmol), 0.336 g paraformaldehyde (11.3 mmol), and 4.5 g of propylphenone (33.58 mmol) were stirred under reflux in a sealed vial. The system was turned off after three hours and partitioned three times with water/ethyl acetate. The aqueous phase was collected and dried under vacuum. The small solid

residue was solubilized in acetone and crystallized overnight at a low temperature (0 °C). The crystals were filtered and recrystallized to obtain 2.0 g of compound 4 (7.5 mmol, hydrochloride salt) with a yield of 66%.

Compounds 5 and 6

1-(morpholin-4-yl)decan-3-one and 3-[(morpholin-4-yl)methyl]nonan-2-one:

For compounds 5 and 6, 100 mL of anhydrous ethanol 5.5 g of morpholine hydrochloride (44.5 mmol), 1.35 g paraformaldehyde (45 mmol), and 2.46 g 2-nonanone (17 mmol) were stirred under reflux in a sealed vial. The system was turned off after four hours and partitioned three times with water/hexane. The aqueous phase was collected and dried under vacuum. The small brown solid was solubilized in acetone/methanol and crystallized at low temperature (0 °C). The crystals were filtered and recrystallized to obtain a mixture of the two isomeric forms (kinetic and thermodynamic) of compounds 5 and 6 in proportions of 48–52 w/w. As a result, a total yield of 3.85 g (14.0 mmol mixture of hydrochloride salt) was obtained with 82% ketone yield.

Compounds 7 and 8

1-(piperidin-1-yl)decan-3-one and 3[(piperidin-1-yl)methyl]nonan-2-one:

For compounds 7 and 8, 100 mL of anhydrous ethanol, 1.76 g of piperidine hydrochloride (14.5 mmol), 0.446 g paraformaldehyde (14.5 mmol), and 6.15 g of 2-nonanone (43.3 mmol) were stirred under reflux in a sealed vial. The system was turned off after four hours and partitioned three times with water/ethyl acetate. The aqueous phase was collected and dried under vacuum. The small solid residue was solubilized in ethanol and crystallized overnight at a low temperature (0 °C). The crystals were filtered and recrystallized to obtain 3.0 g of a mixture of isomers 7 and 8 (10.89 mmol, hydrochloride salt) in 75% yield. High-resolution mass spectrometry (HRMS) (ESI/Q-TOF) m/z: [M+H]⁺ found for C₁₅H₃₀NO 240.2322, err = -2.6 ppm.

PURIFICATION

The compounds were purified by preparative reverse phase high performance liquid chromatography (RP-HPLC) using a preparative Shim-pack C18 column and Shimadzu HPLC System and CH₃CN-H₂O/MeOH-H₂O as solvents, normal phase (silica gel 60) using hexane/ethyl acetate as solvents, or selective crystallization by partial solubilization and decreasing solvent temperature. TLC using HF254 silica plates (Merck) and MeOH/dichloromethane (DCM) as eluents and spots were visualized under visible light or in a UV chamber to monitor the reactions.

STRUCTURAL ELUCIDATION

The compounds were elucidated using high-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) of ¹H and ¹³C. HRMS was performed using a maXis ETD high-resolution ESI-QTOF mass spectrometer (Bruker) controlled by the Compass1.5 software package (Bruker). Data-dependent fragment

spectra were recorded in the collision energy range of 15–60 eV. The ion cooler settings were optimized within a 40–1000 m z-1 range using a calibrant solution of 1 mmol l⁻¹ sodium formate in 50% 2-propanol. Nuclear magnetic resonance (NMR) spectra of ¹H and ¹³C were obtained in a Bruker DRX400 device using deuterium oxide as the solvent and 400 MHz and 100 MHz for ¹H and ¹³C, respectively. Infrared spectra were recorded using an FTIR 8400 Shimadzu spectrophotometer.

Compound 1

3-(morpholin-4-yl)-1-phenylpropan-1-one (AB1)

¹H NMR (400 MHz, D₂O): δ = 3.28–3.33 (m, 4H), 3.63–3.73 (m, 4H), 3.94–3.98 (m, 4H), 7.56–7.62 (m, 2H), 7.71–7.76 (m, 1H), 8.01–8.06 (m, 2H); ¹³C NMR (100 MHz, D₂O): δ = 43.11, 52.01, 52.15, 63.68, 128.18, 128.92, 134.52, 135.29, 199.59 ppm. HRMS: *m/z* calcd for C₁₃H₁₈NO₂ [M+H]⁺: 220.1337; found: 220.1332.

Compound 2

1-phenyl-3-(piperidin-1-yl)propan-1-one

¹H NMR (400 MHz, D₂O): δ = 8.02 (d, 2H, *J* = 8.4 Hz), 7.72 (t, 1H, *J* = 7.4 Hz), 7.58 (t, 2H, *J* = 8.08 Hz), 3.59 (d, 2H, *J* = 11.5 Hz), 3.53 (s, 2H), 3.02 (t, 2H, *J* = 10 Hz), 1.95 (s, 2H), 1.78 (d, 4H, *J* = 12 Hz); ¹³C NMR (100 MHz, D₂O): δ = 199.8, 199.8, 135.3, 134.5, 128.9, 128.1, 53.5, 51.7, 51.6, 22.7, 21.0 ppm. HRMS: *m/z* calcd for C₁₄H₂₀NO [M+H]⁺: 218.1545; found: 218.1539.

Compound 3

2-methyl-3-(morpholin-4-yl)-1-phenylpropan-1-one

¹H NMR (400 MHz, D₂O): δ = 8.06 (d, 2H, *J* = 8.4 Hz), 7.75 (t, 1H, *J* = 7.4 Hz), 7.61 (t, 2H, *J* = 8.1 Hz), 4.26–4.17 (m, 1H), 3.97 (t, 1H, *J* = 5.0 Hz), 3.85 (dd, 3H, *J* = 13.3 Hz, 9.2 Hz), 3.35 (d, 2H, *J* = 3.8 Hz), 3.32 (d, 2H, *J* = 3.9 Hz), 1.31 (d, 3H, *J* = 7.3 Hz); ¹³C NMR (100 MHz, D₂O): δ = 203.4, 134.7, 134.1, 129.1, 128.7, 63.5, 63.4, 58.4, 52.4, 43.1, 36.7, 16.6 ppm. HRMS: *m/z* calcd for C₁₄H₂₀NO₂ [M+H]⁺: 234.1494; found: 234.1489.

Compound 4

2-methyl-1-phenyl-3-(piperidine-1-yl)propan-1-one

¹H NMR (400 MHz, D₂O): δ = 8.06 (d, 2H, *J* = 8.4 Hz), 7.74 (t, 1H, *J* = 7.5 Hz), 7.60 (t, 2H, *J* = 7.6 Hz), 4.21–4.13 (m, 1H), 3.73 (dd, 1H, *J* = 13.4 Hz, 9.2 Hz), 3.53 (t, 2H, *J* = 15.4 Hz), 3.25 (d, 2H, *J* = 3.8 Hz), 3.21 (d, 2H, *J* = 3.8 Hz), 2.99 (q, 2H, *J* = 12.0 Hz), 1.91 (d, 2H,

J = 14.4 Hz), 1.49 (t, 1H, *J* = 12.4 Hz), 1.28 (d, 3H, *J* = 7.3 Hz); ¹³C NMR (100 MHz, D₂O): δ = 203.7, 134.7, 134.2, 129.1, 128.7, 57.9, 54.2, 53.7, 44.5, 36.9, 16.7 ppm. HRMS: *m/z* calcd for C₁₅H₂₁NO [M+H]⁺: 232.1701; found: 232.1696.

Compounds 5 and 6 (mixture)

1-(morpholin-4-yl)decan-3-one and 3-[(morpholin-4-yl)methyl]nonan-2-one

¹H NMR (400 MHz, D₂O): δ = 3.69 (dd, 4H, *J* = 13.4 Hz, 9.8 Hz), 3.46 (t, 8H, *J* = 6.9 Hz), 3.24–3.10 (m, 6H), 2.59 (t, 2H, *J* = 7.4 Hz), 2.33 (s, 8H), 1.79–1.55 (m, 4H), 1.29 (s, 16H), 0.87 (s, 6H); ¹³C NMR (100 MHz, D₂O): δ = 213.5, 212.3, 63.6, 63.4, 56.4, 51.9, 51.7, 46.7, 42.3, 35.7, 30.9, 30.7, 29.4, 28.2, 28.1, 28.0, 25.3, 23.0, 21.9, 21.8, 13.3, 13.2 ppm. HRMS: *m/z* calcd for C₁₄H₂₈NO₂ [M+H]⁺: 242.2120; found: 242.2115.

Compounds 7 and 8 (mixture)

1-(piperidin-1-yl)decan-3-one and 3-[(piperidin-1-yl)methyl]nonan-2-one

¹H NMR (400 MHz, D₂O): δ = 3.61–3.50 (m, 2H), 3.37 (t, 2H, *J* = 6.9 Hz), 3.30–3.24 (m, 10H), 3.13–2.90 (m, 7H), 2.34 (s, 3H), 1.94–1.48 (m, 12H), 1.28 (s, 18H), 0.86 (s, 6H); ¹³C NMR (100 MHz, D₂O): δ = 213.2, 211.3, 56.0, 54.4, 53.4, 51.2, 47.2, 42.4, 36.3, 31.2, 30.9, 29.8, 28.6, 28.5, 28.4, 28.3, 25.5, 23.2, 22.8, 22.6, 22.4, 22.2, 22.0 ppm. HRMS: *m/z* calcd for C₁₅H₃₀NO [M+H]⁺: 240.2327; found: 240.2322.

EVALUATION OF MOLECULAR DOCKING OF PHYSICOCHEMICAL AND ADMET PROPERTIES

All compounds were designed using the MarvinSketch[®] software program (ChemAxon, Cambridge, MA, USA), and the molecular structures were refined using the MOPAC[®] software (Stewart Computational Chemistry, Colorado Springs, CO, USA). The compounds were subjected to molecular docking calculations using the AutoDock Vina[®] program⁴³. All calculations were performed using OCTOPUS[®] program to optimize the virtual screening process. The configuration files were determined using a re-docking step^{44,45,46}. Table 1 lists the molecular targets of the BraMMT.

The physicochemical properties of the eight compounds (1–8) were analyzed using the DataWarrior[®] software and SwissADME website⁴⁷. Finally, toxicological characteristics of the compounds, such as mutagenicity, tumorigenicity, and irritability, were analyzed using DataWarrior^{®48}.